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SUMMARY
The keystone of the adaptive immune response is T cell receptor (TCR) recognition of peptide
presented by Major Histocompatibility Complex (pMHC) molecules. The co-crystal structure of
AHIII TCR bound to the MHC, HLA-A2, showed a large interface with an atypical binding
orientation. MHC mutations in the interface of the proteins were tested for changes in TCR
recognition. From the range of responses observed, three representative HLA-A2 mutants, T163A,
W167A, and K66A, was selected for further study. Binding constants and co-crystal structures of
the AHIII TCR and the three mutants were determined. K66 in HLA-A2 makes contacts with both
peptide and TCR and previously has been identified as a critical residue for recognition by numerous
TCR. The K66A mutation resulted in the lowest AHIII T cell response and the lowest binding affinity,
which suggests T cell response may correlate with affinity. Importantly, the K66A mutation does
not affect the conformation of the peptide. The change in affinity appears to be due to a loss in
hydrogen bonds in the interface as a result of a conformational change in the TCR complementarity-
determining region 3 (CDR3) loop. Isothermal titration calorimetry confirmed the loss of hydrogen
bonding by a large loss in enthalpy. Our findings are inconsistent with the notion that the CDR1 and
CDR2 loops of the TCR are responsible for MHC restriction, while the CDR3 loops interact solely
with the peptide. Instead, we present here a MHC mutation that does not change the conformation
of the peptide, yet results in an altered conformation of a CDR3.
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INTRODUCTION
T cells are an integral part of the adaptive immune system’s ability to recognize virtually any
pathogen that might attack the host. A critical step required for T cell activation is the
recognition of peptides derived from these pathogens when presented by the Major
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Histocompatibility Complex protein (MHC). Recognition of foreign peptide bound to MHC
is achieved through the clonotypic T cell receptor (TCR). Upon TCR recognition of a peptide
bound to MHC (pMHC) sets of T cells either kill the cell presenting the foreign peptide
(cytotoxic T cells) or produce cytokines to “help” B cells and other T cells (helper T cells).
The pathogens are subsequently eliminated from the host by a combination of killing infected
cells to remove reservoirs of replicating pathogen, and antibody-mediated neutralization of the
pathogen outside of the cell. Although TCR binding to pMHC is paramount for T cell
activation, there are still many unanswered questions regarding how TCR-pMHC interactions
dictate T cell response.
Recognition of pMHC by the TCR heterodimer is accomplished using the three
complementarity determining region (CDR) loops from each chain. The CDR1 and CDR2
loops are germ-line encoded within the variable gene segment of each TCRα and TCRβ chain.
The CDR3 loop of each chain is unique and arises through V(D)J recombination 1; 2. While
recognition of the pMHC is carried out using all the CDR loops of each chain, generally the
CDR3 makes more contacts with the bound peptide than CDR1 and CDR2 3.
Engagement of TCR with pMHC may result in a variety of reactions from the T cell, and the
mechanisms that generate these different responses are not understood 3. The structures of
TCR bound to partial agonist or antagonist pMHC complexes do not show changes in the TCR
domains 4; 5 that would suggest a way for the TCR to propagate a qualitatively different signal
to the T cell through the plasma membrane. It is generally accepted that there is great plasticity
in the interaction between TCR and pMHC. However, as seen in a variety of TCR-pMHC co-
crystal structures the degree and location of this plasticity is not generalizable. For example,
the co-crystal structures of 2C-dEV8/Kb 6, 2C-SIYR/Kb 4, and KB5-C20-pKB1/Kb 7 when
compared to crystal structures of those TCRs alone show great flexibility in the CDR3 loops
of the TCR. The LC13 8 and BM3.3 9 TCRs undergo changes in not just their CDR3s, but also
their CDR1 and CDR2 loops. Conversely, the A6-Tax/A2 10 and ELS4-EPLP/B*3501 11 co-
crystal structures exhibit conformational changes in the peptides upon TCR-pMHC binding.
Finally, the crystal structures of the 1G4 TCR alone and complexed with its pMHC ligands
show no significant changes in either the TCR or the pMHC 12.
Similarly, there appear to be no general thermodynamic rules that describe TCR binding to
pMHC. Although surface plasmon resonance (SPR) has been used for more than a decade to
examine binding of TCR to pMHC, it measures kinetic constants between TCR and pMHC
and binding via Scatchard Analysis or mathematically using the kinetic constants. Isothermal
titration calorimetry (ITC) provides a direct measure of ΔH and is hence considered a more
reliable determination of thermodynamic parameters. ITC has been rarely utilized for TCR-
pMHC studies because of the much larger amounts of protein required for the studies. Early
experiments suggested that TCR-pMHC interactions seem to be governed by large
enthalpically favorable and entropically unfavorable thermodynamics 13; 14; 15; 16. However,
more recent thermodynamic data of L13-FLR/B8 17, A6-Tax/A2 18, and 2C-QL9/Ld 19 all
show entropically favorable associations.
The human MHC, HLA-A2, is the most frequent MHC found in Caucasians and African
Americans 20. A large panel of A2 mutants were created and tested against a panel of T cells.
Most interesting from that study, the K66A mutant was found to adversely affect recognition
of 98% of the T cells examined 21. K66 has been shown to be a critical residue in TCR
recognition of A2, regardless of the peptide presented 21; 22; 23; 24, resulting in K66 to be
labeled a potential “hot spot” for TCR recognition of A2. Importantly, even though K66
interacts with the peptide, the structure of Tax/A2(K66A) shows that the K66A mutation does
not alter the structure of A2 or the conformation of the Tax peptide 24. However, the effect of
the K66A mutation on the cognate TCR has never been determined structurally.
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AHIII12.2 (AHIII) is a murine T cell clone that recognizes human HLA-A2.1 25 when peptide
1049 (ALWGFFPVL) is presented 26. Reactivity towards p1049/A2 does not require binding
of the TCR co-receptor CD8, 27 which allows for the study of TCR-pMHC interactions without
the additional complexity of the third protein. We have previously described the crystal
structure of the AHIII TCR complexed with p1049/A2 28. From the AHIII-p1049/A2 co-
crystal structure, we identified a number of A2 surface residues that may be responsible for
binding the AHIII TCR. These residues were mutated in A2 and the changes in T cell cytolytic
activity were examined as a function of the mutation. Three mutants were then selected for
kinetic, thermodynamic, and structural studies. Most importantly, the K66A mutation causes
substantial changes to cytotoxicity and the affinity. This change in affinity appears to be due
to a large reduction in hydrogen bonding that is a result of a large conformational change in
the CDR3 loop. This loss of hydrogen bonding is reflected in the almost complete loss of
enthalpy in the binding reaction.
RESULTS
AHIII T Cell Reactivity
Based on the co-crystal structure of AHIII bound to p1049/A2 28, thirteen HLA-A2 mutations
were selected to probe the interface. The ability of AHIII T cells to lyse target cells expressing
this panel of A2 variants was assessed by loading the target cells with radioactive chromium
(51Cr), incubating the T cells with the target cells for four hours and then measuring the
radioactivity released to the media. Measured lysis was normalized to AHIII lysis of wild-type
A2 expressing cells in each experiment. A spectrum of responses to the mutations was seen
(Figure 1). Some of the mutants showed little affect on reactivity (E166A and T163A). On the
other end of the spectrum the K66A mutation almost completely abolished the response. In
addition to the K66 “hot spot” in A2 21; 22; 23; 24, it has been suggested that positions 65,
69, and 155 could be critical to MHC-restriction due to the high frequency with which they
are seen contacting TCRs in determined TCR-pMHC structures 3; 29; 30. Consistent with
those data, mutations at positions 65, 69, and 155 all had deleterious effects on AHIII
cytotoxicity.
Three A2 variants that represent the range of T cell reactivity were chosen for further study:
T163A (high), W167A (medium), and K66A (low). Mutant proteins were expressed
recombinantly as inclusion bodies in E. coli and refolded in vitro with p1049 peptide. Binding
to the recombinant AHIII TCR was measured using surface plasmon resonance (SPR). Binding
curves for these three complexes in addition to wild-type A2 are shown in Figure 2. The
mutations in the MHC cause significant changes to the affinity for AHIII TCR (Table 1) with
Kd values ranging from 4.7 μM (p1049/A2(T163A)) to 31.8 μM (p1049/A2(K66A)). The
kinetics were also dramatically affected. The dissociation rates (koff) were both faster and
slower than wild-type p1049/A2 (0.27 s-1). Interestingly, even though the affinity of AHIII for
p1049/A2(K66A) is significantly lower than for wild-type A2, the dissociation rate is
significantly slower (Figure 2 and Table 1). Association rates (kon) were generally less affected
by the substitutions, except for p1049/A2(K66A) (4.7 × 103 M-1s-1), which has a much slower
on-rate compared to wild-type A2 (3.1 × 104 M-1s-1).
Structural Analysis of A2 Variants
The physical manifestation of the differences found in T cell recognition and binding was
examined using x-ray crystallography. The three mutants described above (A2(K66A) A2
(T163A) and A2(W167A)) were co-crystallized with AHIII TCR. The locations of the
mutations in the interface between the AHIII TCR and p1049/A2 are shown in Figure 3. Based
on previous work, 5 it seemed unlikely that these relatively small alterations would cause large
changes in the overall structures of the TCR or pMHC, or the docking orientation of the TCR.
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Therefore, we hypothesized that the substitutions resulted in local alterations in the MHC or
peptide, changing hydrogen bonds or van der Waals contacts present in our previously
determined AHIII-p1049/A2 structure 28. Crystallographic data were collected from three
single co-crystals comprised of AHIII TCR complexed with p1049/A2(T163A), p1049/A2
(W167A), or p1049/A2(K66A), to a resolution of 2.4 Å, 2.5 Å, and 2.88 Å, respectively. All
the crystals were nearly isomorphous with AHIII-p1049/A2 28. Data collection and refinement
statistics can be found in Table 2.
As might be expected because of the similar level of T cell activity, no gross structural changes
were observed in the structure of p1049/A2(T163A) bound to AHIII TCR (Figure 4a). For all
three structures superimposition was performed using the “align” feature in PyMol 31,
restraining the alignment to the α-carbons of the TCR-pMHC interface (TCR Vα, Vβ; and
MHC α1, α2 and peptide). The AHIII-p1049/A2(T163A) complex superimposed onto AHIII-
p1049/A2 with an RMSD of 0.20 Å2. Difference electron density (Fobswild-type - Fobsmutant)
maps show a large negative electron density peak in the position of the mutated residue that
demonstrates the quality of the data and confirms the location of the mutation (Figure 4a). One
change in the TCR was observed. The side chain of serine 99 in the TCR CDR3α has rotated
into the cavity where the MHC threonine side chain is found in the wild-type structure.
Interestingly, the electron density maps show the location of the serine without ambiguity, but
there are no contacts visible for the serine side chain. This side chain orientation is not the most
preferred rotamer 32; that preferred conformation is found in the wild-type structure. Therefore,
it may be that this position is taken to reduce undesired energetic contributions to the binding
such as the fixation of solvent or the production of a cavity in the interface.
In addition to its importance to this study concerning T cell reactivity, the A2(W167A) complex
was also interesting because W167 forms a boundary of the peptide-binding cleft (Figure 3)
and helps form the conserved pocket that binds the amino terminus of the peptide 33. This
tryptophan is highly conserved in not only HLA-A2 subtypes (96%), but across all human class
I MHC molecules (88.5%) 34. Mutating tryptophan to alanine results in the loss of a hydrogen
bond between the Trp indol nitrogen to the Tyr28 hydroxyl on the TCR CDR2 (Figure 4b).
Aside from the loss of the W167-Y28 hydrogen bond, the structure of AHIII bound to p1049/
A2(W167A) shows no significant changes in the peptide amino terminus, the CDR2α or
CDR3α of the AHIII TCR, or the MHC itself. The mutant complex alpha carbons have an
RMSD of 0.27 Å2 when superimposed onto the wild-type atoms. The difference electron
density (Fobswild-type - Fobsmutant) map once again shows a large negative peak in the position
of the mutated residue demonstrating the quality of the data and confirming the loss of the Trp
side chain. Two side chains in A2 near the site of mutation do change conformation, but these
differences do not alter binding to the TCR. The amino terminus of the peptide is still
coordinated by hydrogen bonds to three tyrosine hydroxyl groups Tyr7, Tyr 159, and Tyr171
of the MHC, as in wild-type p1049/A2. The AHIII-p1049/A2(W167A) structure shows weak
positive difference density in the location where the nitrogen of the indole ring of wild-type
Trp167 would be (data not shown). This suggests that there may be a weakly associated water
molecule replacing the amine, which could hydrogen bond to the hydroxyl group on Tyr28 of
CDR2α.
The structure of AHIII bound to p1049/A2(K66A) is critical to this study because of the
significantly different binding constants of A2(K66A) (Table 1). Additionally, K66 on the α1
α helix of HLA-A2 has been identified as a “hot spot” for TCR recognition of HLA-A2 in a
number of studies 21; 22; 23; 24. Structures of A6-Tax/A2 10; 35 and AHIII-p1049/A2 28 also
show that K66 is rare in that it makes critical contacts with both the TCR and the peptide. K66A
mutants have increased peptide dissociation rates; yet this is not likely to be responsible for
the decrease in T cell function because T cell clones have also been identified that do not have
altered recognition to the K66A mutation 21; 22. Furthermore, the K66A mutation does not
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alter the MHC structure or the conformation of the Tax peptide in Tax/A2(K66A) 24. So, if
increased peptide dissociation from A2(K66A) mutants does not influence T cell activation,
and the pMHC molecular surface is not altered by the mutation, the next logical hypothesis
would be that the K66A variation results in a change in the TCR that negatively affects T cell
function.
The co-crystal structure of AHIII-p1049/A2(K66A) determined to 2.88 Å resolution shows an
altered conformation of the CDR3α of the AHIII TCR (Figure 4c). The AHIII-p1049/A2
(K66A) structure superimposes onto AHIII bound to wild-type A2 with an RMSD of 0.37
Å2. The 2Fo-Fc electron density maps show the new conformation of the loop (Figure 4d) and
this location is confirmed by omit maps. The conformational change in CDR3α is that the loop
appears to fill the void left by the removal of the Lys66 side chain. The Cα atoms of the loop
move, on average, 2.0 Å with Ala97 moving over 4.0 Å (Table 3). This altered conformation
of the loop likely disrupts the hydrogen bonding contacts found in the native structure 28
between the CDR3α and wild-type p1049/A2 (Figure 4e). In a manner similar to the Tax/A2
(K66A) structure 24, the K66A mutation does not change MHC or peptide conformation in
this AHIII-p1049/A2(K66A) structure. The CDR3 loop change also negatively affects the
surface complementarity (SC). The SC value for the wild-type AHIII-p1049/A2 structure is
0.71 and drops to 0.55 for AHIII-p1049/A2(K66A).
The Tax/A2(K66A) structure showed a water molecule replacing the Lys66 side chain,
mediating hydrogen bonds between Glu63 of A2 and the Tax peptide 24. There is no electron
density that would suggest a water replaces the Lys66 side chain in our AHIII-p1049/A2
(K66A) structure. It appears that the new conformation of the CDR3α loop pushes further into
the peptide binding cleft along the MHC α1 α helix where the Lys66 side chain would have
been, displacing any water that might have filled the void before TCR binding. The number of
reflections associated with the 2.88 Å resolution data can not support the modeling of water
molecules in the structure of AHIII-p1049/A2(K66A). However, there is a small volume in
the 2Fo-Fc electron density map that suggests that there may be a weakly associated water
molecule that would hydrogen bond with Glu63 of A2 and Ser100 on CDR3α of AHIII (Figure
4f). The only other plausible hydrogen bond between the AHIII CDR3α to p1049/A2(K66A)
is from the Ser102 nitrogen to the Gly4 oxygen of the peptide (2.88 Å) (Figure 4f). In summary,
there is a large alteration in the AHIII CDR3α loop when bound to p1049/A2(K66A) as
compared to the wild-type complex and this alteration appears to dramatically change the
number of hydrogen bonds in the complex.
Calorimetric measurement of AHIII TCR and HLA-A2 binding
The altered hydrogen bonding pattern proposed here based on the crystal structure of AHIII-
p1049/A2(K66A) suggests that there should be a large change in the enthalpy of binding. To
examine this directly, the heat of binding was measured using isothermal titration calorimetry
(ITC). Our data show that the wild-type complex binding has a relatively small enthalpic
component (-3.9 kcal/mol) and that the binding is more entropically driven (Table 4 and Figure
5a). As predicted, this small enthalpic contribution to binding is almost completely eliminated
by mutation of K66 to alanine. This change is manifest clearly during the experiments because
the K66A mutation changes the reaction from exothermic to endothermic (Figure 5b). The
enthalpy of binding (ΔH) goes from -3.9 kcal/mol for AHIII-p1049/A2 to almost zero (-0.6
kcal/mol) for AHIII-p1049/A2(K66A). The free energy of binding (ΔG) measured for the two
complexes is in agreement with those determined for other TCR-pMHC (Table 4). The
thermodynamic changes for AHIII-p1049/A2(K66A) correspond to a ΔΔG of only 1.4 kcal/
mol, which highlights the tight range between activating and non-activating signals for TCR.
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The initial goal of this study was to determine how structural alterations in the TCR are
responsible for the spectrum of T cell cytolysis by AHIII T cells. Mutations in HLA-A2 were
made and changes in cytolysis examined as a function of the mutation. Recombinant protein
for three A2 variants was produced and binding constants were determined by surface plasmon
resonance (SPR). Surprisingly, A2(K66A) showed very different kinetic constants as
compared to the wild-type complex. Structural studies showed that most hydrogen bonds
involving the CDR3α loop in the complex were lost upon mutation. Isothermal titration
calorimetry (ITC) confirmed a greatly decreased enthalpy of binding associated with the
conformational change of the loop.
Based on the AHIII-p1049/A2 co-crystal structure previously determined 28, A2 residues that
were predicted to be involved in binding the AHIIII TCR were mutated. The AHIII T cells
reacted with a full spectrum of outcomes from very low cytotoxicity to slightly improved
cytotoxicity as a result of changing residues in the interface between the proteins. Residues at
positions 66 21; 22; 23; 24 and 65, 69, and 155 3; 29; 30 have all been previously identified
as critical contacts in a number of TCR-pMHC systems. Mutations at all of these four of these
positions in A2 resulted in a reduction of AHIII T cell cytotoxicity of 30% to almost 100%.
Clearly, these residues are critical for AHIII TCR binding. As an important control, it has been
shown previously that peptide binding does not change significantly for the mutations studied
except K66A (it has a faster peptide off-rate) 22. However, this faster peptide off-rate cannot
account for the changes in activity because T cells can be found that are not affected by the
K66A mutation 21; 22. This implies that significant peptide bound to MHC remains on the
cell surface even with the K66A mutation. In addition, the expression levels of the various
mutants studied here were confirmed to be similar by flow cytometry (data not shown).
Therefore, any observed changes in reactivity, binding, or structure should be due to changes
in how the complexes interact. A more thorough study of how those mutations resulted in a
change of function was then initiated.
A sub-set of the MHC mutants that represent dramatically reduced to full reactivity (K66A,
W167A, and T163A, respectively) were chosen to study the physical manifestation of the
differences. TCR-pMHC binding studies were performed using SPR. While all mutants showed
some degree of change from wild-type A2, the K66A mutation resulted in remarkably slower
on and off-rates than the wild-type complex. The three mutant complexes were then co-
crystallized with AHIII TCR. The structures were determined and compared to the wild-type
co-crystal structure. Similar to the results seen for the altered peptide ligands for the Tax/A2
specific TCR 5, there were no gross differences in any of the structures examined. Significantly,
there were no changes in domain packing of the TCR that would suggest a mode to transmit
information through the domains to the interior of the cell to confer different activities, as
previously suggested 14. There is always the possibility that the domain movements are
dynamic and/or weakly manifested and are overcome here by crystal packing forces that would
make it impossible to view using protein crystallography. Similarly, it has been suggested that
upon TCR-pMHC interaction, a conformational change in the AB loop of the TCR Cα domain
is required for signaling into the cell 8. Although the position of the AB loop for the non-
liganded AHIII TCR is unknown, the loop in the AHIII TCR bound to all p1049/A2, even
p1049/A2(K66A), is identical, and is the same conformation as seen in the liganded LC13 TCR
8. Importantly, the AB loop in the AHIII structures are not involved in any crystal contacts.
These data imply that the AB loop has no impact on the level of cytotoxicity seen in the AHIII
system.
There are no definitive structural explanations for the “improved” AHIII T cell reactivity for
the A2(T163A) mutant. With threonine being conserved in 98% of all known HLA-A2
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subtypes 34, we had expected a greater impact mutating it to alanine. If anything, the rotation
of the TCR CDR3α Ser99 into the cavity formed by the removal of the MHC threonine side
chain would be expected to contribute negatively to the binding due to the less favorable
rotamer that is chosen. There are no hydrogen bonding partners near the new position of the
serine hydroxyl. There is no significant increase in the complementarity in the fit between the
complexes. The complementarity of fit of AHIII to p1049/A2(T163A) is 0.72 versus 0.71 for
the wild-type structure. We conclude that the most likely explanation for the slightly increased
binding affinity is that there is a set of very subtle changes that increase the complementarity
of fit.
The A2(W167A) mutation results in a 20% loss in lysis by the AHIII T cells. There are no
significant structural changes other than the loss of the W167-Y28 hydrogen bond. Loss of the
W167 indole also affects surface complementarity between AHIII-p1049/A2(W167A) (SC =
0.68) compared to AHIII-p1049/A2 (SC = 0.71). Therefore, the dramatic loss of affinity to the
AHIII TCR is likely a result of the lost hydrogen bond and the concomitant loss of
complementarity (ie van der Waals contacts). The fact that the absence of the indole group
from the end of the peptide binding cleft in the AHIII-p1049/A2(W167A) structure did not
significantly alter the conformation of the bound peptide is surprising. Tryptophan is present
at position 167 in 96% of all known HLA-A2 subtypes and 88.5% conserved in all human class
I MHC molecules 34. It begs the question, why is this amino acid so highly conserved?
Unfortunately, the data provided in the AHIII-p1049/A2(W167A) structure are unable to
address this.
Of all the mutants tested, the K66A mutation caused the largest decrease in AHIII cytolysis.
The slow on-rate seen for AHIII-p1049/A2(K66A) and significant energy barriers measured
for other TCR-pMHC 36; 37 imply that there are structural changes associated with binding,
and in fact, a large change was seen in the CDR3α loop of the AHIII TCR. This suggests that
binding requires a conformational change in the TCR, but when exactly does this occur? Does
the AHIII TCR make initial contact with p1049/A2(K66A) and then the CDR3α loop moves
(induced-fit) or does p1049/A2(K66A) associate with a minority member of the population of
the AHIII TCRs in solution (pre-existing equilibrium). The induced-fit or two-step model 38
has been a popular means of describing TCR-pMHC interaction. However, the validity of the
two-step model has been questioned by both thermodynamic 36 and structural 8; 9; 12 data.
We propose that a pre-existing equilibrium model better describes TCR-pMHC association.
The idea that CDR loops exist in alternative pre-existing conformations in solution has been
shown in antibody crystal structures 39. Knowing the structural similarities between antibodies
and TCR, it is easy to imagine this binding mechanism to exist for TCR and pMHC. The total
number of possible conformations that the CDR loops can adopt is finite and limited by the
conserved framework regions of the TCR and/or antibody structure 40; 41; 42; 43. The residues
that constitute the loop will maintain phi and psi angles that allow for the lowest potential
energy. Loops in higher potential energy conformations would be found less often in the
population (minority member). Therefore, the pMHC surface that allows the TCR to have the
greatest number of its CDR loops in conformations with the lowest energy would provide the
most stable interaction, a higher affinity, and subsequent greater activation of the T cell. The
structural and thermodynamic data presented here for AHIII TCR-p1049/A2(K66A)
demonstrates this relationship between energetics and activation. When the CDR3α loop is
required to take a conformation with higher energy, the interactions between TCR and pMHC
suffer, and T cell activation is adversely affected. As there is not currently a structure of the
AHIII TCR alone, we cannot be sure where the CDR3α loop lies when it is free in solution.
However, the on-rate of AHIII-p1049/A2(K66A) being an order of magnitude slower than
wild-type AHII-p1049/A2 binding, suggests the loop to undergo greater change in order to
bind p1049/A2(K66A) than wild-type p1049/A2. We propose the TCR conformations seen in
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our AHIII-p1049/A2(K66A) complex are minor in the population, so the longer kon is a
reflection of the unfavorable equilibrium of the pMHC binding that minority member.
The AHIII-p1049/A2(K66A) structure also suggested most of the hydrogen bonds found
between AHIII CDR3α and wild-type p1049/A2 are not present in the mutant structure. The
conformational change in CDR3α potentially leaves only the Ser102 to Gly4 hydrogen bond.
This suggested that the enthalpy of binding is greatly diminished. The ITC data complement
the structural data, as it shows there is a significant loss in binding enthalpy. Due to the small
amount of heat absorbed upon AHIII-p1049/A2(K66A) binding, the titration curve generated
is not satisfactory to allow for confident analysis of the entropy in the system. However, the
endothermic binding combined with the loss of enthalpy suggests that the binding of AHIII
TCR to p1049/A2(K66A) is nearly entirely entropically driven. For TCR-pMHC complexes
where heats of binding have been measured directly (and inferred from van’t Hoff calculations),
the enthalpic and entropic contributions are different for each TCR-pMHC system without any
unifying thermodynamic properties. Originally it was thought that TCR-pMHC interactions
were governed by enthalpically favorable and entropically unfavorable thermodynamics
features 13; 14; 15; however, AHIII-p1049/A2 joins LC13-FLR/B8 17, A6-Tax/A2 18, and
2C-QL9/Ld 19 as TCR-pMHC systems that rely on entropically favorable binding.
One of the difficulties associated with studying diverse receptor systems such as TCR
recognition of pMHC is that it is difficult to extract general rules about the system. However,
in the context of what has been done with other TCR-pMHC, there are some general features
that we can present from these data. Previous structural studies have highlighted TCR
recognition of altered peptide ligands 5; 12, different peptides presented by the same MHC 4;
6; 9; 44, or the effects of mutation in the TCR to binding 45, but not the structural effects of
MHC mutation on TCR-pMHC binding. The effects of mutations in the MHC through
biological readout, co-crystal structures, and thermodynamics suggest a correlation between
T cell response and affinity. As many as 32 hydrogen bonds determine specificity in BM3.3-
pBM1/Kb 44, but only 21 in AHIII-p1049/A2 28 and approximately 15 in the AHIII-p1049/
A2(K66A) complex. The recently determined structure of 2C-QL9/Ld 19 reveals an interface
with less than 10 hydrogen bonds and entropically favorable binding. What does this say about
specificity? If there are no hydrogen bonds determining specificity, the only way the TCR can
be sure to only recognize the foreign complex must be complementarity of fit. Not surprisingly
perhaps, AHIII-p1049/A2 28 and 2C-QL9/Ld 19 have the greatest complementarity of fit of
all TCR-pMHC structures determined to date. In addition to other published results, our data
suggest that the thermodynamics for each TCR-pMHC interaction is unique. The large range
of thermodynamic constants reveals that there are many ways to get to T cell activation. This
all suggests that the pathways to activation are not important, just the end point.
Most importantly, the AHIII-p1049/A2(K66A) structure provides evidence that a variation in
the MHC and not the peptide can directly affect a CDR3 loop. The idea of CDR1 and CDR2
recognition of MHC followed by CDR3 binding to peptide works for a select few TCR, but
not for most. In the case of K66, Lys is not conserved across all MHC (93% of HLA-A2
subtypes, but only 42.5% conserved in HLA-A overall, and only 1.5% of HLA-B molecules
34). Therefore, the presence of this charge is not required, but can be thought of as another
piece of the antigen surface. TCR recognition of the pMHC surface cannot be divorced into
separate binding events of peptide and MHC.
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Cell Lines and Expression Plasmids
The HLA-A2 mutants transfected into Hmy2.C1R cells have been described previously 23.
All cell lines showed cell surface expression of HLA-A2 at similar levels as wild-type HLA-
A2 as detected by the HLA-A2-specific Ab BB7.2 48.
Protein Production and Purification
Soluble AHIII12.2 TCR was produced as previously described 28. Briefly, the ectodomains
of AHIII TCR α and β chains were expressed as inclusion bodies in E. coli. Purified inclusion
bodies, previously dissolved in 8M urea, were rapidly injected into a folding buffer optimized
for the AHIII TCR at a concentration of 50 μg/ml. After incubation for 36 hours at 10 °C and
extensive dialysis the native TCR was purified and concentrated by DE52 anion exchange
(Whatman, Florham Park, NJ)) followed by gel filtration chromatography (Phenomenex,
Torrance, CA) on HPLC. The purified AHIII TCR was concentrated to 10 mg/ml and stored
at -80 °C. Soluble AHIII TCR was tested for proper folding and activity through an ELISA
using HLA-A2 tetramer. Typical yield for each 1 L refold is about 3-5 mg of active TCR.
Similarly, soluble HLA-A2 variants were produced as inclusion bodies in E. coli and refolded
in vitro 49. Peptide p1049 (ALWGFFPVL), presented by A2, was synthesized by the UNC
Peptide Synthesis Facility (Chapel Hill, NC). Briefly, peptide, β2m, and heavy chain were
injected in that order into a folding buffer optimized for refolding class I MHC at a
concentration of 50 μg/ml. After incubation for 24-36 hours at 10 °C the folded pMHC was
concentrated in an Amicon ultrafiltration cell (Millipore, Billerica, MA) and purified using gel
filtration chromatography (Phenomenex) on HPLC. The purified wild-type and A2 variants
were concentrated to 10 mg/ml and stored at -80°C. Typical yield for each 1 L refold is about
5 mg of pMHC.
Cytotoxicity Assay
Cytotoxicity was assayed using a standard 4 hour 51Cr release assay as described previously
50. Briefly, between 5.0 × 103 and 5.0 × 104 AHIII 12.2 T cells were incubated with 5000
peptide-pulsed 51Cr-labeled A2 mutant-transfected cells. Since p1049 is a human self-antigen,
the transfectants were recognized without the addition of p1049 to the cells. Additional p1049
did not increase cytotoxicity (data not shown).
Surface Plasmon Resonance Experiments
Five-thousand resonance units (RUs) of H57-597 (capturing molecule, anti-TCR Cβ Ab) were
covalently bound to a Biacore CM5 sensor chip (Uppsala, Sweden) using standard amine
coupling. Soluble AHIII12.2 TCR (ligand) was then added to the Ab at a concentration of
50-100 nM to generate 300-400 RU of bound TCR. Soluble class I MHC (analyte) was injected
onto the surface at a flow rate of 100 μl/min in a 30-s pulse. TCR and MHC were removed
from the surface with 0.1 M Glycine, 0.5 M NaCl, pH 2.5, and the procedure was repeated
until at least three curves were obtained for the different concentrations of analyte. Curves
obtained at each concentration were subtracted from a reference surface that contained Ab
alone without TCR or using recombinant P14 TCR as a negative control. Data were processed
using Scrubber (BioLogic Software, Campbell, Australia) and CLAMP 51. The suitability of
the fit was measured based on χ2 values and the appearance of residuals. In all cases, χ2 was
below 1, residuals were small and random, and the experimental curves visually matched the
predicted curves.
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Protein Crystallization and Structure Determination
The crystallization conditions for the co-crystal complexes were similar to those optimized for
AHIII TCR with wild-type A2 28. Briefly, crystals are grown by hanging drop, vapor diffusion,
using AHIII TCR and A2 variants mixed at equal ratios at a concentration of 10 mg/ml. Drops
contain 1 μl of protein mixed with 1 μl of a well solution containing Hepes, pH 7.5-8.0, 1 M
NaCl, and 14%-18% PEG 8000. Small crystals formed within 3 days along with precipitate in
drops. Crystal size was improved by macro-seeding into identical conditions. Crystals were
transferred to mother liquor containing 25% glycerol as cryoprotectant. Crystallographic data
were collected at Southeast Regional Collaborative Access Team (SER-CAT) 22-ID and 22-
BM beamlines at the Advanced Photon Source, Argonne National Laboratory (Argonne, IL).
Data for AHIII-p1049/A2(T163A) was collected on the 22-BM beamline at 12,398.42 eV for
360° at a distance of 200 mm using 1.0° oscillations. Two datasets for AHIII-p1049/A2
(W167A) were collected on the 22-ID beamline at 12,759.89 eV at a distance of 300 mm using
1.0° oscillations. 180° were collected at an omega angle of 90° and an additional 45° was
collected at an omega of 45°. These data sets were indexed separately and then scaled together.
Data for AHIII-p1049/A2(K66A) was collected on the 22-ID beamline at 12,759.89 eV for
180° at a distance of 300 mm using 1.0° oscillations. Data for all co-crystal complexes were
indexed and scaled with HKL2000 52. The data for AHIII-p1049/A2(T163A) was originally
collected out to 2.1 Å, but it was highly anisotropic. As a result, the statistics in the highest
shells were poor, so the data was truncate at 2.4 Å. Molecular replacement solutions were
determined using Rigid Body Refinement in Refmac 5.0 53 with AHIII-p1049/A2 (1LP9)
28 as the search model. Temperature factors were set to 30.0 using Moleman 54. Positional
refinement using noncrystallographic symmetry restraints for the first few cycles and TLS
refinement 55 in Refmac 5.0 was performed iteratively with manual intervention with O 56.
When the statistics did not improve over two subsequent rounds of refinement and the Rfree
was below 30%, waters were added using Arp within Refmac 5.0 to AHIII-p1049/A2(T163A)
and AHIII-p1049/A2(W167A) models. All waters were examined to confirm the presence of
hydrogen bond donors or acceptors at reasonable geometries. For the AHIII-p1049/A2(K66A)
model, an omit map of the CDR3α loop was generated to verify the conformational change.
The refinement statistics for the final models are presented in Table 2. Surface complementarity
(SC) calculated using Sc 57 in CCP4 53.
Isothermal Titration Calorimetry
ITC experiments on AHIII TCR with wild-type p1049/A2 and p1049/A2(K66A) were
performed on a Microcal VP-ITC in the UNC Macromolecular Interactions Facility (Chapel
Hill, NC). Thermodynamic constants were obtained for AHIII TCR binding wild-type p1049/
A2 as well as p1049/A2(K66A) by fitting the calorimetric data using a one-site binding model
in Microcal Origin Version 5.0 Software (OriginLab Corporation, Northampton, MA). Soluble
AHIII TCR was placed in the mixing chamber. p1049/A2 or p1049/A2(K66A) was titrated
into the AHIII TCR solution until binding reached saturation. Titration of wild-type p1049/A2
into AHIII TCR was performed in duplicate, once in Phosphate buffer, pH 7.5, and then in Tris
buffer, pH 7.5, to ensure that the determined enthalpy was not affected by ionization enthalpy
of the buffer 58. Concentrations of AHIII TCR and p1049/A2 were 17 μM and 217 μM,
respectively, in Phosphate and 19 μM and 234 μM, respectively in Tris. For wild-type p1049/
A2 experiments, a volume of 3 μL was used for the first four injections, and then 5 μL for the
remaining titrations. The baseline, generated by averaging the heat measured for the last 10
injections, was subtracted from all peaks. Titration of p1049/A2(K66A) in AHIII TCR was
performed in triplicate in Phosphate buffer, pH 7.5. Concentrations of AHIII TCR and p1049/
A2(K66A) were 40 μM and 618 μM, 65 μM and 450 μM, and 43 μM and 394 μM, respectively,
for the three replicates. For all p1049/A2(K66A) experiments, 5 μL was injected for the first
four peaks, increasing to 10 μL for the remainder of the experiment. Because of the relatively
small amount of heat released upon AHIII-p1049/A2(K66A) binding, a more accurate baseline
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was determined by injecting p1049/A2(K66A) into Phosphate buffer to measure heat of
dilution. This reference data set was then subtracted from the experimental data set in Origin
Software. All concentrations were determined before the proteins were placed in the
microcalorimeter using extinction coefficients. ΔH and ΔS were calculated using the Origin
software. Gibbs free energy was calculated as ΔG = ΔH - TΔS, T = 298 K.
ACKNOWLEDGEMENTS
We thank William E. Biddison, Ph.D. of the Molecular Immunology Section of the National Institutes of Health,
Bethesda, MD for supplying the HLA-A2 variant cells lines for our cytotoxicity assays. Data were collected at
Southeast Regional Collaborative Access Team (SER-CAT) 22-ID beamline at the Advanced Photon Source, Argonne
National Laboratory. Staff at the beamline are acknowledged for assistance in data collection. Use of the Advanced
Photon Source was supported by the U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences,
under Contract No. W-31-109-Eng-38. The director of the UNC Macromolecular Interations Facility, Ashutosh
Tripathy, Ph.D. is gratefully acknowledged for his assistance with collecting and interpreting ITC data. Members of
the Collins and Frelinger labs are acknowledged for helpful discussions.
References
1. Schatz DG, Spanopoulou E. Biochemistry of V(D)J recombination. Curr Top Microbiol Immunol
2005;290:49–85. [PubMed: 16480039]
2. Spicuglia S, Franchini DM, Ferrier P. Regulation of V(D)J recombination. Curr Opin Immunol
2006;18:158–63. [PubMed: 16459067]
3. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev
Immunol 2006;24:419–66. [PubMed: 16551255]
4. Degano M, Garcia KC, Apostolopoulos V, Rudolph MG, Teyton L, Wilson IA. A functional hot spot
for antigen recognition in a superagonist TCR/MHC complex. Immunity 2000;12:251–61. [PubMed:
10755612]
5. Ding YH, Baker BM, Garboczi DN, Biddison WE, Wiley DC. Four A6-TCR/peptide/HLA-A2
structures that generate very different T cell signals are nearly identical. Immunity 1999;11:45–56.
[PubMed: 10435578]
6. Garcia KC, Degano M, Pease LR, Huang M, Peterson PA, Teyton L, Wilson IA. Structural basis of
plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 1998;279:1166–72.
[PubMed: 9469799]
7. Reiser JB, Gregoire C, Darnault C, Mosser T, Guimezanes A, Schmitt-Verhulst AM, Fontecilla-Camps
JC, Mazza G, Malissen B, Housset D. A T cell receptor CDR3beta loop undergoes conformational
changes of unprecedented magnitude upon binding to a peptide/MHC class I complex. Immunity
2002;16:345–54. [PubMed: 11911820]
8. Kjer-Nielsen L, Clements CS, Purcell AW, Brooks AG, Whisstock JC, Burrows SR, McCluskey J,
Rossjohn J. A structural basis for the selection of dominant alphabeta T cell receptors in antiviral
immunity. Immunity 2003;18:53–64. [PubMed: 12530975]
9. Reiser JB, Darnault C, Gregoire C, Mosser T, Mazza G, Kearney A, van der Merwe PA, Fontecilla-
Camps JC, Housset D, Malissen B. CDR3 loop flexibility contributes to the degeneracy of TCR
recognition. Nat Immunol 2003;4:241–7. [PubMed: 12563259]
10. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between
human T-cell receptor, viral peptide and HLA-A2. Nature 1996;384:134–41. [PubMed: 8906788]
11. Tynan FE, Reid HH, Kjer-Nielsen L, Miles JJ, Wilce MC, Kostenko L, Borg NA, Williamson NA,
Beddoe T, Purcell AW, Burrows SR, McCluskey J, Rossjohn J. A T cell receptor flattens a bulged
antigenic peptide presented by a major histocompatibility complex class I molecule. Nat Immunol
2007;8:268–76. [PubMed: 17259989]
12. Chen JL, Stewart-Jones G, Bossi G, Lissin NM, Wooldridge L, Choi EM, Held G, Dunbar PR, Esnouf
RM, Sami M, Boulter JM, Rizkallah P, Renner C, Sewell A, van der Merwe PA, Jakobsen BK,
Griffiths G, Jones EY, Cerundolo V. Structural and kinetic basis for heightened immunogenicity of
T cell vaccines. J Exp Med 2005;201:1243–55. [PubMed: 15837811]
Miller et al. Page 11













13. Lee JK, Stewart-Jones G, Dong T, Harlos K, Di Gleria K, Dorrell L, Douek DC, van der Merwe PA,
Jones EY, McMichael AJ. T cell cross-reactivity and conformational changes during TCR
engagement. J Exp Med 2004;200:1455–66. [PubMed: 15583017]
14. Krogsgaard M, Prado N, Adams EJ, He XL, Chow DC, Wilson DB, Garcia KC, Davis MM. Evidence
that structural rearrangements and/or flexibility during TCR binding can contribute to T cell
activation. Mol Cell 2003;12:1367–78. [PubMed: 14690592]
15. Willcox BE, Gao GF, Wyer JR, Ladbury JE, Bell JI, Jakobsen BK, van der Merwe PA. TCR binding
to peptide-MHC stabilizes a flexible recognition interface. Immunity 1999;10:357–65. [PubMed:
10204491]
16. Garcia KC, Radu CG, Ho J, Ober RJ, Ward ES. Kinetics and thermodynamics of T cell receptor-
autoantigen interactions in murine experimental autoimmune encephalomyelitis. Proc Natl Acad Sci
U S A 2001;98:6818–23. [PubMed: 11391002]
17. Ely LK, Beddoe T, Clements CS, Matthews JM, Purcell AW, Kjer-Nielsen L, McCluskey J, Rossjohn
J. Disparate thermodynamics governing T cell receptor-MHC-I interactions implicate extrinsic
factors in guiding MHC restriction. Proc Natl Acad Sci U S A 2006;103:6641–6. [PubMed:
16617112]
18. Davis-Harrison RL, Armstrong KM, Baker BM. Two different T cell receptors use different
thermodynamic strategies to recognize the same peptide/MHC ligand. J Mol Biol 2005;346:533–50.
[PubMed: 15670602]
19. Colf LA, Bankovich AJ, Hanick NA, Bowerman NA, Jones LL, Kranz DM, Garcia KC. How a single
T cell receptor recognizes both self and foreign MHC. Cell 2007;129:135–46. [PubMed: 17418792]
20. Ellis JM, Henson V, Slack R, Ng J, Hartzman RJ, Katovich Hurley C. Frequencies of HLA-A2 alleles
in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231. Hum
Immunol 2000;61:334–40. [PubMed: 10689125]
21. Baker BM, Turner RV, Gagnon SJ, Wiley DC, Biddison WE. Identification of a crucial energetic
footprint on the alpha1 helix of human histocompatibility leukocyte antigen (HLA)-A2 that provides
functional interactions for recognition by tax peptide/HLA-A2-specific T cell receptors. J Exp Med
2001;193:551–62. [PubMed: 11238586]
22. Baxter TK, Gagnon SJ, Davis-Harrison RL, Beck JC, Binz AK, Turner RV, Biddison WE, Baker
BM. Strategic mutations in the class I major histocompatibility complex HLA-A2 independently
affect both peptide binding and T cell receptor recognition. J Biol Chem 2004;279:29175–84.
[PubMed: 15131131]
23. Wang Z, Turner R, Baker BM, Biddison WE. MHC allele-specific molecular features determine
peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors. J
Immunol 2002;169:3146–54. [PubMed: 12218132]
24. Gagnon SJ, Borbulevych OY, Davis-Harrison RL, Baxter TK, Clemens JR, Armstrong KM, Turner
RV, Damirjian M, Biddison WE, Baker BM. Unraveling a hotspot for TCR recognition on HLA-A2:
evidence against the existence of peptide-independent TCR binding determinants. J Mol Biol
2005;353:556–73. [PubMed: 16197958]
25. Engelhard VH, Benjamin C. Isolation and characterization of monoclonal mouse cytotoxic T
lymphocytes with specificity for HLA-A,B or -DR alloantigens. J Immunol 1982;129:2621–9.
[PubMed: 6982933]
26. Henderson RA, Cox AL, Sakaguchi K, Appella E, Shabanowitz J, Hunt DF, Engelhard VH. Direct
identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells.
Proc Natl Acad Sci U S A 1993;90:10275–9. [PubMed: 7694286]
27. Buslepp J, Kerry SE, Loftus D, Frelinger JA, Appella E, Collins EJ. High affinity xenoreactive
TCR:MHC interaction recruits CD8 in absence of binding to MHC. J Immunol 2003;170:373–83.
[PubMed: 12496422]
28. Buslepp J, Wang H, Biddison WE, Appella E, Collins EJ. A correlation between TCR Valpha docking
on MHC and CD8 dependence: implications for T cell selection. Immunity 2003;19:595–606.
[PubMed: 14563323]
29. Tynan FE, Burrows SR, Buckle AM, Clements CS, Borg NA, Miles JJ, Beddoe T, Whisstock JC,
Wilce MC, Silins SL, Burrows JM, Kjer-Nielsen L, Kostenko L, Purcell AW, McCluskey J, Rossjohn
Miller et al. Page 12













J. T cell receptor recognition of a ‘super-bulged’ major histocompatibility complex class I-bound
peptide. Nat Immunol 2005;6:1114–22. [PubMed: 16186824]
30. Clements CS, Dunstone MA, Macdonald WA, McCluskey J, Rossjohn J. Specificity on a knife-edge:
the alphabeta T cell receptor. Curr Opin Struct Biol 2006;16:787–95. [PubMed: 17011774]
31. Delano, WL. The PyMOL Molecular Graphics System. DeLano Scientific; San Carlos, CA: 2002.
32. Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, Richardson JS,
Richardson DC. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins
2003;50:437–50. [PubMed: 12557186]
33. Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol
1995;13:587–622. [PubMed: 7612235]
34. Robinson J, Waller MJ, Parham P, de Groot N, Bontrop R, Kennedy LJ, Stoehr P, Marsh SG. IMGT/
HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex.
Nucleic Acids Res 2003;31:311–4. [PubMed: 12520010]
35. Ding YH, Smith KJ, Garboczi DN, Utz U, Biddison WE, Wiley DC. Two human T cell receptors
bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino
acids. Immunity 1998;8:403–11. [PubMed: 9586631]
36. Davis-Harrison RL, Insaidoo FK, Baker BM. T Cell Receptor Binding Transition States and
Recognition of Peptide/MHC. Biochemistry 2007;46:1840–50. [PubMed: 17249694]
37. Wu W, Harley PH, Punt JA, Sharrow SO, Kearse KP. Identification of CD8 as a peanut agglutinin
(PNA) receptor molecule on immature thymocytes. J Exp Med 1996;184:759–64. [PubMed:
8760831]
38. Wu LC, Tuot DS, Lyons DS, Garcia KC, Davis MM. Two-step binding mechanism for T-cell receptor
recognition of peptide MHC. Nature 2002;418:552–6. [PubMed: 12152083]
39. James LC, Roversi P, Tawfik DS. Antibody multispecificity mediated by conformational diversity.
Science 2003;299:1362–7. [PubMed: 12610298]
40. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies
D, Tulip WR, et al. Conformations of immunoglobulin hypervariable regions. Nature 1989;342:877–
83. [PubMed: 2687698]
41. Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G.
Structural repertoire of the human VH segments. J Mol Biol 1992;227:799–817. [PubMed: 1404389]
42. Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of
immunoglobulins. J Mol Biol 1997;273:927–48. [PubMed: 9367782]
43. Morea V, Tramontano A, Rustici M, Chothia C, Lesk AM. Conformations of the third hypervariable
region in the VH domain of immunoglobulins. J Mol Biol 1998;275:269–94. [PubMed: 9466909]
44. Reiser JB, Darnault C, Guimezanes A, Gregoire C, Mosser T, Schmitt-Verhulst AM, Fontecilla-
Camps JC, Malissen B, Housset D, Mazza G. Crystal structure of a T cell receptor bound to an
allogeneic MHC molecule. Nat Immunol 2000;1:291–7. [PubMed: 11017099]
45. Borg NA, Ely LK, Beddoe T, Macdonald WA, Reid HH, Clements CS, Purcell AW, Kjer-Nielsen L,
Miles JJ, Burrows SR, McCluskey J, Rossjohn J. The CDR3 regions of an immunodominant T cell
receptor dictate the ‘energetic landscape’ of peptide-MHC recognition. Nat Immunol 2005;6:171–
80. [PubMed: 15640805]
46. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-
likelihood method. Acta Crystallogr D Biol Crystallogr 1997;53:240–55. [PubMed: 15299926]
47. Reed, N. S. P. a. R. J. Improved Structure Refinement Through Maximum Likelihood. Acta
Crystallogr A 1996;52:659–668.
48. Brodsky FM, Parham P, Barnstable CJ, Crumpton MJ, Bodmer WF. Monoclonal antibodies for
analysis of the HLA system. Immunol Rev 1979;47:3–61. [PubMed: 95015]
49. Garboczi DN, Hung DT, Wiley DC. HLA-A2-peptide complexes: refolding and crystallization of
molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl
Acad Sci U S A 1992;89:3429–33. [PubMed: 1565634]
50. Loftus DJ, Chen Y, Covell DG, Engelhard VH, Appella E. Differential contact of disparate class I/
peptide complexes as the basis for epitope cross-recognition by a single T cell receptor. J Immunol
1997;158:3651–8. [PubMed: 9103427]
Miller et al. Page 13













51. Myszka DG, Morton TA. CLAMP: a biosensor kinetic data analysis program. Trends Biochem Sci
1998;23:149–50. [PubMed: 9584619]
52. Otwinowski, Z. a. M., M. CarterCWJ. a. R. M. S.Macromolecular Crystallography, part A edit.
Methods in Enzymology. Processing of X-ray Diffraction Data Collected in Oscillation
Mode1997276Academic PressNew York
53. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr
1994;50:760–3. [PubMed: 15299374]
54. Kleywegt, GJ. Uppsala University; Uppsala, Sweden: 19922004.
55. Winn MD, Isupov MN, Murshudov GN. Use of TLS parameters to model anisotropic displacements
in macromolecular refinement. Acta Crystallogr D Biol Crystallogr 2001;57:122–33. [PubMed:
11134934]
56. Jones TA, Zou JY, Cowan SW, Kjeldgaard. Improved methods for building protein models in electron
density maps and the location of errors in these models. Acta Crystallogr A 1991;47(Pt 2):110–9.
[PubMed: 2025413]
57. Lawrence MC, Colman PM. Shape complementarity at protein/protein interfaces. J Mol Biol
1993;234:946–50. [PubMed: 8263940]
58. Baker BM, Murphy KP. Evaluation of linked protonation effects in protein binding reactions using
isothermal titration calorimetry. Biophys J 1996;71:2049–55. [PubMed: 8889179]
Miller et al. Page 14













Figure 1. CTL Killing as a Function of Substitutions in the p1049/A2 Complex
Cytotoxic lysis assays (51Cr release assays) were performed with AHIII T cells against cells
expressing mutant A2 complexes. Data was normalized such that lytic activity against native
HLA-A2 is 100%.
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Figure 2. AHIII TCR binding to p1049/A2 variants as measured by SPR
Kinetic data between AHIII TCR and wild-type p1049/A2 as well as p1049/A2 mutants at
various pMHC concentrations were obtained using SPR and globally fit to a reversible
bimolecular reaction using Clamp 51. Model binding curves are drawn in black. Curve fits are
drawn in grey.
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Figure 3. Structure of AHIII TCR bound to p1049/A2
The AHIII TCR alpha (green) and beta (blue) chains, interact with the p1049/A2 surface via
CDR loops. HLA-A2, consisting of a heavy chain (yellow) and β2m (magenta), present the
peptide, p1049 (red). (Inset) The surface of the p1049/A2 is contacted by the CDR loops of
the AHIII TCR. Residues that have been mutated to alanine for structural experiments (T163,
W167, K66) are shown. Figure generated using PDB coordinates 1LP9 and PyMol 31.
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Figure 4. Mutation of Lys66 to alanine results in large change in CDR3α loop
(a) Complex of AHIII TCR bound to p1049/A2(T163A) superimposed onto wild-type structure
of AHIII-A2. Mutant A2 (cyan) and peptide (blue) show little difference from wild-type A2
(yellow) and peptide (orange). Conformations of TCR CDR2 and CDR3 loops and side chains
are no different between mutant (magenta) and wild-type (green) structures (coloring scheme
same for all panels). (b) Complex of AHIII TCR bound to p1049/A2(W167A) also shows no
change in TCR structure and only minor alterations in local MHC side chains. (c)
Superimposition with of AHIII TCR bound to p1049/A2(K66A) onto wild-type shows a major
rearrangement of the AHIII CDR3α loop, while the structure of pMHC remains unchanged.
(a, b, c) Mutations at T163A, W167A, and K66A are confirmed by difference electron density
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(Fobswild-type - Fobsmutant) contoured at -3σ surrounding the side chains. (d) 2Fobs-Fcalc
density map (blue), contoured at 1 σ, confirms placement of final modeled CDR3α loop at 2.88
Å. (e) Five hydrogen bond interactions occur between AHIII TCR CDR3α and wild-type
p1049/A2. As shown above some or all of these bonds may be broken due to loop movement.
(f) The 2Fobs-Fcalc electron density suggests the presence of a water molecule in the AHIII-
p1049/A2(K66A) structure, which would allow for a water-mediated hydrogen bond between
Glu63 of A2 and Ser100 on CDR3α of AHIII (water shown for illustration, but not included
in PDB). The only other possible hydrogen bond to CDR3α is from the Ser102 nitrogen to the
Gly4 oxygen of the peptide. Figures generated using PyMol 31.
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Figure 5. K66A mutation in p1049/A2 dramatically decreases the enthalpy of binding
The binding enthalpy of AHIII TCR was measured directly with ITC for both wild-type p1049/
A2, and p1049/A2(K66A). (a) Power versus molar ratio plot for titration of 234 μM p1049/A2
into 19 μM of AHIII TCR (upper panel) and plot of integrated heat versus molar ratio after
baseline correction (lower panel). The baseline was generated by averaging heat measured for
last 10 injections. (b) Plot of power versus molar ratio for titration of 394 μM p1049/A2(K66A)
into 40 μM of AHIII TCR (upper panel) and integrated heat versus molar ratio after baseline
correction (lower panel). The baseline derived from titrating p1049/A2(K66A) into buffer
alone. All experiments performed at 25 °C. The fitted curves are from the model for single-
site binding provided in Microcal Origin Software. Thermodynamic parameters determined
are presented in Table 4.
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Table 1
Equilibrium and kinetic binding parameters for AHIII TCR binding p1049/A2 mutants.
pMHC Complex Kd Equilibrium (μM) Kd Kinetic (μM) kon (×10
4 M-1s-1) koff (s
-1)
p1049/A2 9.3 8.7 3.1 0.27
p1049/A2(T163A) 4.7 4.6 3.3 0.16
p1049/A2(W167A) 15.4 14.8 4.1 0.63
p1049/A2(K66A) 31.8 34.0 0.47 0.15
Parameters were obtained by fitting data with Scrubber 2.0 and CLAMP. Kinetic dissociation constants (Kd) were obtained from kinetic data using the
determined kon and koff values. Equilibrium dissociation constants were obtained separately by fitting maximum binding responses for various
concentrations of pMHC using Scrubber.


















Space Group P21 P21 P21
Cell Dimensions a=93.49 Å, b=84.18 Å,
c=121.77 Å, β=92.05°
a=94.28 Å, b=84.35 Å,
c=122.47 Å, β=92.53°
a=93.42 Å, b=83.89 Å,
c=122.27 Å, β=92.21°
Molecules/AU 2 2 2
Resolution 50.0 - 2.10 Å 50.0 - 2.5 Å 50.0 - 2.88 Å
Rmerge(%)
a,b 5.9 (46.7) 6.6 (31.8) 7.8 (42.1)
<I/σ>c 11.4 (1.6) 18.0 (1.8) 11.2 (1.3)
Unique Reflections 76,682 61,781 40,707
Avg. Redundancy 2.7 (1.7) 4 (2.5) 3.4 (2.3)
Completeness (%) 70.0 (24.7) 92.8 (67.8) 95.7 (69.0)
Solvent Content (%) 41.5 40.7 44.1
Refinement
Resolution Range 30.0 - 2.4 Å 30.0 - 2.5 Å 30.0 - 2.88 Å
Number of Reflections 59,694 58,660 38,683
Rfac
d 24.0 25.3 26.8
Rfree 28.9 29.9 29.3
Number of non-H atoms 13,160 12,995 12,956
Number of waters modeled 267 52 0
<Rs fit>e 93% 93% 90%
Coordinate errorf, 46; 47 0.25 0.32 0.46
Deviations from ideality
 Bond lengths 0.006 Å 0.006 Å 0.005 Å
 Bond angles 1.040° 1.192° 0.750°
<Temperature Factor>
 Overall 37.6 49.7 47.2
 TCR 37.8 49.6 47.5
 MHC 37.6 50.1 47.1
 Peptide 34.7 48.6 37.5
Ramachandran
 Most favored 1305 (91.4%) 1291 (90.7%) 1287 (90.4%)
 Additional allowed 121 (8.5%) 131 (9.2%) 134 (9.4%)
 Generously allowed 0 0 0
 Disallowed 2 (0.1%) 2 (0.1%) 2 (0.1%)
PDB Entry 2UWE 2JCC 2J8U
aRmerge = ΣhklΣi ∣ Ii − I ∣ ∕ ΣhklΣi Ii , where Ii is the observed intensity and 〈I〉 is the average intensity of multiple observations of
symmetry related reflections.
b
Number in parentheses refers to highest resolution shell.
c
I/sigI for highest shells : 2.49 - 2.37 Å, 2.59 - 2.50 Å, 3.0 - 2.9 Å (T163A, W167A, and K66A, respectively).
dR = Σhkl ∣ ∣ Fobs ∣ − k ∣ Fcal ∣ ∣ ∕ Σhkl ∣ Fobs ∣  , where Rfree is calculated for a randomly chosen 5% of reflections, Rwork is
calculated for the remaining 95% of reflections used for structure refinement.
e
〈Rs fit〉 is the average real space fit of all atoms on a 2fo- fc electron density map.
f
Error is the mean coordinate error estimate based on maximum likelihood measurements.


























Distances limited to 2 significant figures due to low resolution of AHIII-p1049/A2(K66A).
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